Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must demonstrate willingness to participate in the study.~* Diagnosed with chronic HCV.~* Between 18 and 65 years of age of either gender and of any race.~* a. HCV positive, \>600,000 IU/mL at baseline AND b. Genotype 1.~* Suitable for treatment with Pegetron® per the Canadian product monograph.~* Investigator has already decided to treat with PEGETRON REDIPEN®~1.5mcg/kg/week of peginterferon alpha-2b plus 800-1200 mg /day of ribavirin.~* HCV-RNA negative at treatment week 4.~* Meet certain minimum laboratory values at the week 4 screening visit.~* Women of childbearing potential and male partners must agree to use a medically accepted method of contraception prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, oral or injectable hormonal contraceptive, and surgical sterilization (e.g. hysterectomy or tubal ligation).~Exclusion Criteria:~* Had previous interferon-based therapy for Chronic Hepatitis C.~* Active Hepatitis B virus (HBV) infection.~* Human Immunodeficiency Virus (HIV) antibody positive.~* Cirrhotic (Stage 4 on Metavir system).~* Uncontrolled history or current severe depression or psychoses.~* Uncontrolled epilepsy.~* Use of illicit drugs.~* History of non-compliance to medical regimens.~* Liver disease other than from chronic hepatitis C.~* Participating in any other clinical study.~* Used any investigational drugs within 30 days of screening.~* Participants weighing \< 40 kg or \> 125 kg.~* Pregnant women or women who plan to become pregnant or sexual partners of women who want to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pegetron® - 24 Weeks (Type: EXPERIMENTAL): Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
- Pegetron®- 48 Weeks (Type: ACTIVE_COMPARATOR): Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).